The level of deletion 17p and bi-allelic inactivation of has a significant impact on clinical outcome in multiple myeloma.
作者信息
Thanendrarajan Sharmilan, Tian Erming, Qu Pingping, Mathur Pankaj, Schinke Carolina, van Rhee Frits, Zangari Maurizio, Rasche Leo, Weinhold Niels, Alapat Daisy, Bellamy William, Ashby Cody, Mattox Sandra, Epstein Joshua, Yaccoby Shmuel, Barlogie Bart, Hoering Antje, Bauer Michael, Walker Brian A, Davies Faith E, Morgan Gareth J
机构信息
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
出版信息
Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26.
Abstract
摘要
相似文献
1
The level of deletion 17p and bi-allelic inactivation of has a significant impact on clinical outcome in multiple myeloma.17号染色体短臂缺失水平及双等位基因失活对多发性骨髓瘤的临床结局有显著影响。
Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26.
2
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.17p缺失型骨髓瘤中TP53突变的发生率、时间及对生存的影响
Blood Cancer J. 2017 Sep 15;7(9):e610. doi: 10.1038/bcj.2017.76.
3
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.TP53 基因突变仅与多发性骨髓瘤中的 del(17p)相关。
Haematologica. 2010 Nov;95(11):1973-6. doi: 10.3324/haematol.2010.023697. Epub 2010 Jul 15.
4
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.用常规或沙利度胺为基础的疗法治疗多发性骨髓瘤时，del(17p)的临床影响和分子生物学。
Genes Chromosomes Cancer. 2011 Oct;50(10):765-74. doi: 10.1002/gcc.20899.
5
Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells.骨髓瘤病程中的骨髓发育异常。17号染色体短臂缺失和p53过表达仅限于髓系细胞。
Leukemia. 1998 Feb;12(2):238-41. doi: 10.1038/sj.leu.2400909.
6
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.高亚克隆 17p 缺失分数与多发性骨髓瘤的不良预后相关。
Blood. 2019 Mar 14;133(11):1217-1221. doi: 10.1182/blood-2018-10-880831. Epub 2019 Jan 28.
7
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.del(17p) 伴无 TP53 突变对经强化治疗的新诊断多发性骨髓瘤患者预后不良。
Blood. 2021 Mar 4;137(9):1192-1195. doi: 10.1182/blood.2020008346.
8
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.新诊断多发性骨髓瘤中 17p 缺失的基线特征、染色体改变和影响预后的治疗。
Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.
9
Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.超单倍体浆细胞骨髓瘤，其特征为预后不良、17号染色体单体以及常伴发的TP53突变。
Blood Cancer J. 2019 Feb 19;9(3):20. doi: 10.1038/s41408-019-0182-z.
10
p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.p53 核表达与 TP53 杂合性缺失相关，并且预测接受来那度胺治疗的复发/难治性多发性骨髓瘤患者的不良预后。
Am J Clin Pathol. 2012 Feb;137(2):208-12. doi: 10.1309/AJCPHC85DGAXZDBE.
引用本文的文献
1
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group.多发性骨髓瘤风险分层的细胞遗传学结果检测与报告指南：癌症基因组学联盟浆细胞肿瘤工作组报告
Blood Cancer J. 2025 Jun 18;15(1):86. doi: 10.1038/s41408-025-01286-w.
2
Deletion of 17p in cancers: Guilt by (p53) association.癌症中17号染色体短臂缺失：因（p53）关联而获罪。
Oncogene. 2025 Mar;44(10):637-651. doi: 10.1038/s41388-025-03300-8. Epub 2025 Feb 18.
3
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.高危多发性骨髓瘤定义与管理的证据现状
Curr Oncol Rep. 2025 Mar;27(3):258-277. doi: 10.1007/s11912-025-01639-5. Epub 2025 Feb 12.
4
Evaluation of plasma cell sorting methods in multiple myeloma patients: flow cytometry versus magnetic beads.多发性骨髓瘤患者浆细胞分选方法的评估：流式细胞术与磁珠法
Cancer Cell Int. 2025 Jan 17;25(1):16. doi: 10.1186/s12935-025-03647-8.
5
Prognostic model and immune-infiltrating cell landscape based on differentially expressed autophagy-related genes in TP53-mutated multiple myeloma.基于TP53突变型多发性骨髓瘤中差异表达的自噬相关基因的预后模型及免疫浸润细胞图谱
Arch Med Sci. 2021 Jul 27;20(5):1619-1630. doi: 10.5114/aoms/140293. eCollection 2024.
6
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.从血液系统恶性肿瘤中p53的调控到去调控：对诊断、预后和治疗的影响
Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9.
7
The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma.多发性骨髓瘤中 DNA 损伤反应（DDR）网络与丝裂原活化蛋白激酶（MAPK）信号通路的相互作用。
Int J Mol Sci. 2024 Jun 26;25(13):6991. doi: 10.3390/ijms25136991.
8
Recent Advances in The Definition of the Molecular Alterations Occurring in Multiple Myeloma.多发性骨髓瘤中发生的分子改变定义的最新进展
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024062. doi: 10.4084/MJHID.2024.062. eCollection 2024.
9
Patterns of Aneuploidy and Signaling Consequences in Cancer.癌症中的非整倍体模式和信号后果。
Cancer Res. 2024 Aug 15;84(16):2575-2587. doi: 10.1158/0008-5472.CAN-24-0169.
10
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.新型抗B细胞成熟抗原α-鹅膏蕈碱抗体药物偶联物HDP-101在17p缺失骨髓瘤模型中显示出优于贝兰他单抗马福汀的活性和增强的疗效。
Res Sq. 2024 Jan 11:rs.3.rs-3843028. doi: 10.21203/rs.3.rs-3843028/v1.
本文引用的文献
1
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.双等位基因失活在多发性骨髓瘤复发时更为普遍，将RB1鉴定为一个独立的预后标志物。
Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12.
2
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.通过在美法仑分次移植中添加硼替佐米和沙利度胺，可以克服不良的中期细胞遗传学情况。
Clin Cancer Res. 2017 Jun 1;23(11):2665-2672. doi: 10.1158/1078-0432.CCR-15-2620. Epub 2016 Nov 3.
3
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.克隆选择以及涉及肿瘤抑制基因的双打击事件是骨髓瘤复发的基础。
Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.
4
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.新诊断多发性骨髓瘤中 17p 缺失的基线特征、染色体改变和影响预后的治疗。
Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.
5
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.针对基因表达谱定义的高危多发性骨髓瘤的剂量密集型和低剂量强度的总疗法5
Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64.
6
Clinical value of molecular subtyping multiple myeloma using gene expression profiling.利用基因表达谱分析对多发性骨髓瘤进行分子亚型分型的临床价值
Leukemia. 2016 Feb;30(2):423-30. doi: 10.1038/leu.2015.309. Epub 2015 Nov 3.
7
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
8
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.克隆大小对多发性骨髓瘤中荧光原位杂交染色体异常预后价值的影响。
Clin Cancer Res. 2015 May 1;21(9):2148-56. doi: 10.1158/1078-0432.CCR-14-2576. Epub 2015 Feb 4.
9
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.国际评分系统 3 联合高乳酸脱氢酶水平，以及 t(4;14)和/或 del(17p)，可识别出接受一线自体造血干细胞移植治疗的多发性骨髓瘤 (MM) 患者，这些患者具有早期 MM 进展相关死亡的高风险。
J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329. Epub 2014 Jun 2.
10
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.克隆内异质性是骨髓瘤发生过程中的一个关键早期事件，且发生在临床症状出现之前。
Leukemia. 2014 Feb;28(2):384-390. doi: 10.1038/leu.2013.199. Epub 2013 Jul 2.
Zotero 插件